Professor Vetriselvan Subramaniyan
- Professor
Biography
Professor Vetriselvan Subramaniyan is a distinguished pharmacologist with over fifteen years of teaching and research experience across leading institutions in Malaysia, Ethiopia, and India. He has held key leadership positions, including Acting Dean and Deputy Dean, and has been involved in global health initiatives under the UNDP program. His research, highlighted by over 240 publications and eight international patents, has secured numerous prestigious grants. Dr. Vetriselvan is a fellow of multiple scientific societies, a keynote speaker, Ph.D. examiner, and visiting professor in India and China. He also serves as an overseas executive member of the Indian Pharmacological Society.
Academic & Professional Qualifications
- Certificate in Health Research Fundamentals, Indian Council of Medical Research (2018)
- Ph.D. in Pharmaceutical Science, OPJS University, India (2016)
- M. Pharm in Pharmacology, SASTRA University, India (2008)
- B. Pharm, Annamalai University, India (2005)
- Certificate in Pharmaceutical Formulation, Annamalai University, India (2004)
- Certificate in Quality Control of Drugs, Annamalai University, India (2004)
Research Interests
- Pharmacological Screening
- Toxicology
- Metabolic Diseases
- Disease Management
- Formulation and Development
- Public health
Teaching Areas
- Pharmacology
- Toxicology
Courses Taught
- MBBS
- Pharmacy
- Medical Science
Notable Publications
- Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicology reports. 2021; 8:376-85.
- Gothwal SK, Goyal K, Barjatya HC, Bhakar BL, Dahiya R, Singh Y, Saini TK, Agrawal M, Subramaniyan V, Gupta G. Estimating the correlation between TYG and CIMT in non-diabetic adult patients. Obesity Medicine. 2022; 35:100460.
- Subramaniyan V, Fuloria S, Gupta G, Kumar DH, Sekar M, Sathasivam KV, Sudhakar K, Alharbi KS, Al-Malki WH, Afzal O, Kazmi I. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. Chemico-biological interactions. 2022; 351:109735.
- Reshma A, Tamilanban T, Chitra V, Subramaniyan V, Gupta G, Fuloria NK, Sekar M, Fuloria S, Sahu R, Narayanan J, Chakravarthy S. Anti-obesity effects of olivetol in adult zebrafish model induced by short-term high-fat diet. Scientific reports. 2023;13(1):18449.
- Fuloria S, Subramaniyan V, Karupiah S, Kumari U, Sathasivam K, Meenakshi DU, Wu YS, Sekar M, Chitranshi N, Malviya R, Sudhakar K. Comprehensive review of methodology to detect reactive oxygen species (ROS) in mammalian species and establish its relationship with antioxidants and cancer. Antioxidants. 2021 Jan 18;10(1):128.
- Khan F, Joshi A, Devkota HP, Subramaniyan V, Kumarasamy V, Arora J. Dietary glucosinolates derived isothiocyanates: chemical properties, metabolism and their potential in prevention of Alzheimer’s disease. Frontiers in Pharmacology. 2023; 14:1214881.
- Santhoshkumar T, Govindarajan RK, Kamaraj C, Alharbi NS, Manimaran K, Yanto DH, Subramaniyan V, Baek KH. Biological synthesis of nickel nanoparticles using extracellular metabolites of Bacillus Sphaericus: Characterization and vector-borne disease control applications. South African Journal of Botany. 2023; 162:481-94.
- Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M. Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology. 2023;14:1150270.
- Nag S, Stany B, Mishra S, Kumar S, Mohanto S, Ahmed MG, Mathew B, Subramaniyan V. Multireceptor Analysis for Evaluating the Antidiabetic Efficacy of Karanjin: A Computational Approach. Endocrinology, Diabetes & Metabolism. 2024;7(4):e509.
- Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M. Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology. 2024;15:1343756.
- Kumarasamy V, Anbazhagan D, Subramaniyan V, Vellasamy S. Blastocystis sp., Parasite Associated with Gastrointestinal Disorders: An Overview of its Pathogenesis, Immune Modulation and Therapeutic Strategies. Current Pharmaceutical Design. 2018;24(27):3172-5.
Achievements & Accolades
Title: Evaluation of anti-obesity activity on the natural Karanjin molecule through the adipogenesis pathway using a high-fat diet-induced rat model
Reference: FRGS/1/2023/SKK10/MUSM/02/3
Role: Principal investigator
Funding body: Kementerian Pendidikan Tinggi (Ministry of Higher Education Malaysia)
Period: 2023→ 2026
Title: Unravelling the Gut Microbiome's Role in Epilepsy with Obesity and its Influence on Antiseizure Medication Response using a Rodent Model
Reference: FRGS/1/2024/SKK10/MUSM/03/5
Role: Co-investigator
Funding body: Kementerian Pendidikan Tinggi (Ministry of Higher Education Malaysia)
Period: 2024 → 2027
Title: Elucidating NOD2 Gene Activation and Downstream Signaling Pathways in Colon Cancer Cells Following Exposure to Amebic Cysteine Protease
Reference: Ref: FRGS/1/2024/SKK10/UKM/02/14
Role: Co-investigator
Funding body: Kementerian Pendidikan Tinggi (Ministry of Higher Education Malaysia)
Period: 2024 → 2027
Title: Prevalence of Blastocystis hominis amongst pediatric cancer patients (UKM-SPKPPP-PT(P)08-CRIM-AK01-L02)
Role: Co-investigator
Funding body: The National University of Malaysia Advanced Health and Medicine Research Grant
Period: 01/10/2023 → 30/09/2025
Title: Evaluation of curcumin against TLR4/NF-κB p65 and CYP2E1/ROS/Nrf2 signaling pathways expression in the overabundant ethanol-induced animal model (I-M010-SED-000159)
Role: Principal investigator
Grant type/Organization: Monash University Malaysia
Period: April 2023 → June 2024
Title: Impact of Prolonged Antibiotic Use on Antibiotic Resistance in Immunocompromised Patients: A Comprehensive Review
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Chuah Eei Whey
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: A Review on Antibiotic Resistance Emergence in Immunocompromised Patients
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Sim Hui Jing
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Review on Antibiotic Resistance Development in Patients with Compromised Immune Systems under Prolonged Antibiotic Exposure
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Ngu Michelle Siew Lee
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Evaluating the Relationship Between Prolonged Antibiotic Exposure and Antibiotic Resistance in Immunocompromised Patients: A Comprehensive Review
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Kanesan Daneessa
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Evaluating the Relationship Between Prolonged Antibiotic Exposure and Antibiotic Resistance in Immunocompromised Patients: A Comprehensive Review
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Kanesan Daneessa
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Do and Don’ts in Medication Prescription for COPD and Asthma & Future Innovations
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Lee Darren Huan Ming
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Implementation of Do’s and Don’ts in Medication Prescription for Patients with Asthma and COPD
Type of Project: Scholarly Intensive Placement (SIP)
Role: Main Supervisor
Principal investigator: Tan Vicky
Organization: Monash University Malaysia
Year: 2023
Status: Completed
Title: Implementation of Do’s and Don’ts in Medication Prescription for Patients with Asthma and COPD
Role: Co-supervisor
Principal investigator: Mudasir Lawal
Program: Ph.D.
Organization: Lovely Professional University, India
Period: 2023 → 2026
Status: Ongoing
Title: Discovery of new aldoketo reductase family 1- member C2 (AKR1C2) inhibitors as potential anti-cancer agents using machine learning augmented docking and in vitro bioassay
Role: Co-supervisor
Principal investigator: Kawthar Othman M Aihussinei
Program: Ph.D.
Organization: University Malaya
Period: 2023 → 2026
Status: Ongoing
Title: TLR4/NF-κB and CYP2E1/ROS/Nrf2 Pathways in an Excessive Ethanol-Driven Animal Model: An Observational Study
Role: Main Supervisor
Principal investigator: Eason Kong Qi Zheng
Type of research: Young Scholar Program 2023/2024
Organization: Monash University Malaysia
Period: November 2023 → January 2024
Status: Completed
Professional Associations
- Full Member of the British Pharmacological Society
- Executive and Life member of the Indian Pharmacological Society (IPS)
- Fellow of the Malaysian Scientific Association (FMSA)
- Fellow of Einstein Research Academy (FERA)
- Member of the Malaysian Society of Pharmacology and Physiology (MSPP)
- Vice President of the Association of Pharmacy Professionals (VP-APP
- Malaysian International Branch)
- Life Member of Tamilnadu Pharmacy Council (TNPC)
- Life Member of the Indian Association of Colleges of Pharmacy (IACP)
- Member of Indian Biomedical Scientists (IBS)
- Editorial Board Member of Pharmacological Research (Elsevier)
- Associate editor of Heliyon Journal (Elsevier)
- Editorial member of Scientific Reports (Nature Portfolio)
- Member of The Obesity Society (TOB)
